Loading
InMed Pharmaceuticals Inc. Stock: price and insider trades · United States
1 insider bought €178k of shares over the last 90 days, the latest by ADAR1 Capital Management, LLC, filed 20 Oct 2026.
InMed Pharmaceuticals Inc.: what insiders have been doing
This page follows insider dealings at InMed Pharmaceuticals Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. Over the twelve months to 22 October 2026, 24 filings were filed, from 2 insiders.
The flow runs one way only: 2 insiders bought (24 purchases totalling €829k) and nobody sold on the market. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The buyers include 2 major shareholders. One trade stands out by size: a purchase of €269k from ADAR1 Capital Management, LLC, disclosed on 21 May 2026, or 4.1% of market capitalisation.
With 24 filings in twelve months, the company is quieter than the median of 28 filings across the 5,462 companies we follow on the same exchange. Our records for InMed Pharmaceuticals Inc. go back to 2017, with 64 purchases and 54 sales on the open market in total. The 10-K for the year ended 30 June 2025 shows 4.9 m USD of revenue and -8.2 m USD of net income.
Within a 30-day window, 1 purchase overlapped with buying by a second insider. Purchases made close together by different insiders form what is called a cluster. The last purchase on record was published on 20 October 2026, which is 4 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction.
For comparison within the same sector, see the insider buying recorded at Xenon Pharmaceuticals Inc. and Vivos Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
130
Thresholds
n/a
Buy Volume
€1M
64 ops. · all time
Sell Volume
€2M
54 ops. · all time
Who traded when
BuySaleADAR1 Capital Management, LLC18 buys
Vivo Opportunity, LLC6 buys
Since the insiders bought
- -2.2%Entry US$1.39 · Close 21 Oct 2026 US$1.36
- -10.5%Entry US$1.52 · Close 21 Oct 2026 US$1.36
- -63.1%Entry US$8.14 · Close at T+365 US$3.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 25,185 of 26,248 companies
14.1
score / 100
Value1
Quality28
FCF yld-117%
Earn yld-171%
EV/EBITDA·
ROE-157%
Gross mgn35%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended June 2025 · cache
US$1.34
Analyst consensus
Income statement
RevenueUS$4.9M
Gross profitUS$1.7M35% margin
EBITDA-US$10.7M-216% margin
Net income-US$12.6M0.0% margin
Valuation
P/Book6.7x
Beta0.93
Balance sheet & cash
Market capUS$7.4M
Total debtUS$741.3k
Free Cash Flow-US$8.6M
Debt / Equity6%
Profitability & ownership
ROE-156.8%
ROA-66.5%
% insiders0.1%
% institutions53.5%
Last declaration on 20 October 2026
Declarations130 total
1 shares@ US$1.320.0000% mcap0.0% of flowCommon SharesSEC:0001940272-26-000026:0
Canonical exit: 14 Jan 2027 (T+90)
1,086 shares@ US$1.320.020% mcap0.2% of flowCommon SharesSEC:0001940272-26-000026:1
Canonical exit: 17 Jan 2027 (T+90)
564 shares@ US$1.330.010% mcap0.1% of flowCommon SharesSEC:0001940272-26-000025:0
Canonical exit: 11 Jan 2027 (T+90)
8,021 shares@ US$1.330.15% mcap1.2% of flowCommon SharesSEC:0001940272-26-000025:1
Canonical exit: 12 Jan 2027 (T+90)
984 shares@ US$1.32190.018% mcap0.1% of flowCommon SharesSEC:0001940272-26-000025:2
Canonical exit: 13 Jan 2027 (T+90)
5,601 shares@ US$1.32770.10% mcap0.8% of flowCommon SharesSEC:0001940272-26-000023:0
Canonical exit: 4 Jan 2027 (T+90)
3,046 shares@ US$1.330.055% mcap0.5% of flowCommon SharesSEC:0001940272-26-000023:1
Canonical exit: 5 Jan 2027 (T+90)
2,256 shares@ US$1.32830.041% mcap0.3% of flowCommon SharesSEC:0001940272-26-000023:2
Canonical exit: 6 Jan 2027 (T+90)
16,431 shares@ US$1.32980.30% mcap2.5% of flowCommon SharesSEC:0001940272-26-000022:0
Canonical exit: 30 Dec 2026 (T+90)
8,307 shares@ US$1.330.15% mcap1.3% of flowCommon SharesSEC:0001940272-26-000022:1
Canonical exit: 31 Dec 2026 (T+90)
18,182 shares@ US$1.330.33% mcap2.8% of flowCommon SharesSEC:0001940272-26-000022:2
Canonical exit: 3 Jan 2027 (T+90)
28,505 shares@ US$1.29380.49% mcap4.0% of flowCommon SharesSEC:0001940272-26-000021:0
Canonical exit: 13 Dec 2026 (T+90)
54,256 shares@ US$1.29840.94% mcap7.6% of flowCommon SharesSEC:0001940272-26-000021:1
Canonical exit: 14 Dec 2026 (T+90)
8,340 shares@ US$1.2890.14% mcap1.2% of flowCommon SharesSEC:0001940272-26-000021:2
Canonical exit: 15 Dec 2026 (T+90)
1,000 shares@ US$1.5550.020% mcap0.2% of flowCommon SharesSEC:0001940272-26-000010:0
Canonical exit: 13 Oct 2026 (T+90)
4,882 shares@ US$1.550.100% mcap23.8% of flowCommon SharesSEC:0001213900-26-078891:0
Canonical exit: 12 Oct 2026 (T+90)
493 shares@ US$1.550.010% mcap2.4% of flowCommon SharesSEC:0001213900-26-078891:1
Canonical exit: 12 Oct 2026 (T+90)
13,761 shares@ US$1.550.28% mcap66.9% of flowCommon SharesSEC:0001213900-26-078891:2
Canonical exit: 13 Oct 2026 (T+90)
1,389 shares@ US$1.550.028% mcap6.8% of flowCommon SharesSEC:0001213900-26-078891:3
Canonical exit: 13 Oct 2026 (T+90)
19 shares@ US$1.550.0004% mcap0.1% of flowCommon SharesSEC:0001213900-26-078891:4
Canonical exit: 14 Oct 2026 (T+90)
2 shares@ US$1.550.0000% mcap0.0% of flowCommon SharesSEC:0001213900-26-078891:5
Canonical exit: 14 Oct 2026 (T+90)
68,551 shares@ US$1.59981.45% mcap13.0% of flowCommon SharesSEC:0001940272-26-000008:0
Canonical exit: 17 Aug 2026 (T+90)
200,000 shares@ US$1.56044.13% mcap37.1% of flowCommon SharesSEC:0001940272-26-000008:1
Canonical exit: 17 Aug 2026 (T+90)
200,000 shares@ US$1.4993.97% mcap35.6% of flowCommon SharesSEC:0001940272-26-000008:2
Canonical exit: 17 Aug 2026 (T+90)
240 shares@ US$0.1763100.0% of flowCommon StockSEC:0001213900-24-064728:0
25 of 130 declarations
About InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc. is a biopharmaceutical company listed on the NASDAQ in the United States under the ticker INM. From an equity-analysis perspective, the company is best described as a development-stage biotech with a dual strategy: advancing proprietary small-molecule drug candidates for high-unmet-need diseases, while also maintaining a commercial cannabinoid business through its BayMedica segment. The company’s roots go back to 1981, when it was originally incorporated in British Columbia, and it later adopted the name InMed Pharmaceuticals Inc. in 2014 to reflect a sharper focus on cannabinoid-based pharmaceutical development.
InMed’s core scientific identity is built around cannabinoid research and drug discovery. The company has long emphasized its expertise in compounds that interact with CB1 and CB2 receptors, as well as related biological targets. Its current pipeline is centered on lead assets such as INM-901, which InMed is advancing as a potential treatment for Alzheimer’s disease, and INM-089, which has been developed in an intravitreal formulation for dry age-related macular degeneration. These programs place the company squarely in the high-risk, high-reward category typical of clinical-stage biotech: valuation is driven more by scientific milestones, preclinical readouts, regulatory progress, and partnering potential than by near-term earnings.
Read moreShow less
BayMedica provides a complementary commercial platform. It supplies non-intoxicating rare cannabinoids as raw materials to customers in the health and wellness market. While this business is still relatively small, it gives InMed a modest revenue stream that can help partially offset R&D spending. In the latest company disclosures, BayMedica reported annual sales of about $4.9 million for fiscal 2025, up 8% year over year. That is not enough to make the company self-funding, but it does add strategic flexibility compared with a pure pre-revenue biotech.
Competitively, InMed occupies a niche position. It is not a large-cap pharmaceutical player, but it has differentiated intellectual-property and manufacturing know-how in rare cannabinoids and cannabinoid analogs. That specialization can be a source of edge if the underlying science continues to validate, yet it also means the investment case depends heavily on execution and clinical outcomes. The company’s operational footprint is associated with Vancouver, British Columbia, while its market access and investor visibility are tied to the U.S. public markets via NASDAQ in the United States.
Recent news flow has been important. In 2025 and 2026, InMed highlighted progress in its development programs, including positive preclinical data for INM-901 in human brain organoid neuroinflammation models relevant to Alzheimer’s disease, and the selection of an intravitreal formulation for INM-089. The company also stated that it has strengthened its balance sheet and expects to reach additional development milestones into late 2026. Overall, InMed Pharmaceuticals is a speculative healthcare name with a focused cannabinoid platform, a small commercial revenue base, and meaningful upside potential if its pipeline advances successfully.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
